Research programme: enzyme replacements - Ultragenyx

Drug Profile

Research programme: enzyme replacements - Ultragenyx

Alternative Names: rhPPCA; UX 004

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Ultragenyx Pharmaceutical
  • Class Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lysosomal storage diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA (Parenteral)
  • 26 Feb 2016 Ultragenyx Pharmaceuticals announces intention to submit an IND for UX 004 in 2017 (Ultragenyx Pharmaceuticals, Form 10-K, February 2016)
  • 27 Mar 2015 Ultragenyx Pharmaceuticals in-licenses rhPPCA from St. Jude Children’s Research Hospital (Ultragenyx Pharmaceuticals form 10-K filed in March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top